News articles about Allergan PLC. (NYSE:AGN) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Allergan PLC. earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.7157221482365 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Shares of Allergan PLC. (NYSE:AGN) traded down 0.76% during midday trading on Monday, hitting $227.73. The company had a trading volume of 1,631,578 shares. The company has a market capitalization of $76.13 billion, a P/E ratio of 6.94 and a beta of 1.18. The firm’s 50 day moving average is $238.12 and its 200 day moving average is $237.88. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the firm posted $3.35 EPS. Equities research analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be given a dividend of $0.70 per share. The ex-dividend date of this dividend is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.23%. Allergan PLC.’s payout ratio is 9.95%.

AGN has been the subject of a number of research analyst reports. UBS Group AG reissued a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a report on Monday, May 15th. BidaskClub raised Allergan PLC. from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Royal Bank Of Canada set a $284.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Monday, June 12th. Mizuho lowered their price target on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Finally, Cowen and Company set a $400.00 price target on Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, June 8th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $275.49.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Insider Buying and Selling by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.